BioNet News, Pertussis 17 Jun 2022 Etude Pertagen® 2xÉTUDE SUR PERTAGEN®, UN NOUVEAU VACCIN CONTRE LA COQUELUCHE Statut En cours de recrutement. La coqueluche circule largement chez les jeunes, qui jouent un rôle de réservoir et transmettent… Supachai
BioNet News, Pertussis 26 Feb 2022 Pharmaniaga And Thailand’s BioNet Group Collaborate In Vaccine R&D Pharmaniaga Berhad is looking to collaborate and partner with Thailand’s BioNet Group for vaccine research and development (R&D) and Bio-Innova… Supachai
BioNet News, Pertussis, Publication 06 Dec 2021 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age Background: A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis… Supachai
BioNet News, Pertussis, Press Releases 01 Nov 2018 BioNet acellular pertussis vaccines Publications report Paris, France - BioNet announced today that the one-year antibody persistence results from the phase 2/3 randomized controlled trial of its… Supachai
BioNet News, Pertussis, Press Releases 05 Sep 2018 Boosting Pertussis Vaccination PARIS, GENEVA and BANGKOK September 5, 2018 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT),… Supachai
BioNet News, Pertussis, Press Releases 30 Aug 2017 The HUG completes the PertADO Trial evaluating Pertagen The Geneva University Hospitals has conducted the PertADO Trial, the first clinical study in Europe evaluating Pertagen, a new recombinant… Supachai
BioNet News, Pertussis, Press Releases 03 Mar 2016 BioNet-Asia announces the formation of its Scientific Advisory Board Supachai